News | May 05, 2023
Merck plans bioprocessing center in South Korea
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
Dr. Rishi brings more than 15 years of experience in bioprocess development, microbial fermentation, technology transfer, and biotechnology operations
The cleanroom operates under stringent ISO Class 5 conditions, using ultrapure water and air systems
New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
